Corindus Vascular Robotics (CVRS) Tops Q4 EPS by 1c

Corindus Vascular Robotics (NYSE: CVRS) reported Q4 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $800 thousand.

2017 Guidance

Corindus continues to expect full year 2017 revenue to be in the range of $13 million to $15 million. Corindus expects the implementation of at least 25 new cardiovascular programs in 2017.

For earnings history and earnings-related data on Corindus Vascular Robotics (CVRS) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Home Depot (HD) Tops Q2 EPS by 19c, reaffirms guidance
• Evogene (EVGN) Tops Q2 EPS by 15c